CDKN2AIPNL抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09472(CDKN2AIPNL Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

CDKN2AIPNL (Cyclin-Dependent Kinase Inhibitor 2A Interacting Protein N-Terminal Like) is a protein-coding gene with emerging significance in cellular processes such as cell cycle regulation, apoptosis, and DNA damage response. The encoded protein interacts with p53. a critical tumor suppressor, and modulates its transcriptional activity, suggesting a role in maintaining genomic stability. CDKN2AIPNL is implicated in aging-related pathways and has been studied in contexts like cancer, neurodegeneration, and metabolic disorders due to its potential influence on cellular senescence and stress responses.

Antibodies targeting CDKN2AIPNL are primarily used in research to investigate its expression, localization, and functional mechanisms. These tools enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in the exploration of its tissue-specific roles. Studies have linked altered CDKN2AIPNL expression to diseases such as hepatocellular carcinoma, Alzheimer’s disease, and diabetes, highlighting its dual roles as a potential biomarker or therapeutic target. However, the functional complexity of CDKN2AIPNL, including splice variants and post-translational modifications, necessitates careful antibody validation to ensure specificity. Current research focuses on clarifying its interactions within p53 networks and its broader impact on disease pathogenesis, underscoring its relevance in both basic and translational biomedical studies.